A carregar...
Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6347084/ https://ncbi.nlm.nih.gov/pubmed/30719396 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|